Introduction: Malignant mesothelioma is a deadly disease that is strongly associated with asbestos exposure. Peritoneal mesotheliomas account for 10% of all the cases. BRCA1 associated protein 1 (BAP1) is a deubiquitinating hydrolase that plays a key role in various cellular processes. Germline and somatic inactivation of BRCA1 associated protein 1 gene (BAP1) is frequent in pleural mesothelioma; however, little is known about its status in peritoneal mesothelioma.
Introduction
Breast cancer type 1 susceptibility (BRCA1) associated protein 1 (BAP1) is a deubiquitinating hydrolase that plays a key role in various cellular processes, including regulation of transcription, regulation of cell cycle and growth, response to DNA damage, and chromatin dynamics. [1] [2] [3] [4] Although there was contradictory evidence supporting the tumor suppressor role of BAP1 in cancer, 5 recent genetic evidence from mouse models has proved that BRCA1 associated protein 1 gene (BAP1) is a bona fide tumor suppressor, 6 acting along the lines of a classical twohit tumor suppressor gene. 7 Further supporting this idea, BAP1 inactivation has recently been associated with a tumor predisposition syndrome (BAP1 tumor predisposition syndrome) because germline mutations in this gene predispose families to uveal melanoma, renal cell carcinoma, malignant mesothelioma, and cutaneous melanoma and possibly to a range of other cancers as well. 8 Malignant mesothelioma is a deadly disease that is strongly associated with asbestos exposure. 9 Malignant pleural mesothelioma accounts for more than 85% of malignant mesothelioma cases, whereas peritoneal and pericardial mesotheliomas account for 10% and 5%, respectively, depending on the countries. Germline and somatic inactivation of BAP1 has been recurrently reported in pleural mesothelioma. [10] [11] [12] [13] [14] However, because of its rarity and challenging diagnosis, limited data have been produced on the BAP1 status in peritoneal mesothelioma, with only 13 human tumors included in the largest series sequenced so far. 15, 16 Taking advantage of the extensive French National Network for the Diagnosis of Malignant Pleural Mesothelioma and Rare Peritoneal Tumors and the French National Network for the Treatment of Rare Peritoneal Surface Malignancies, we have been able to collect tumor material, as well as clinical and epidemiological data for 46 patients with peritoneal mesothelioma. We have previously assessed most of these samples for copy number (CN) alterations, 17 and in the present study we aim to complete this information with gene mutation and protein expression data to fully determine the status of BAP1 in peritoneal mesotheliomas.
Material and Methods

Patients and Samples
The patients included in this study belong to the French National Reference Centers for Diagnosis of Mesothelioma and Rare Peritoneal Tumors and for the Treatment of Rare Peritoneal Surface Malignancies. 18, 19 The diagnosis was confirmed as previously described 18, 19 with consensus guidelines established by the International Mesothelioma Interest Group. 20 Asbestos and smoking exposure status were determined at interview during medical consultation. All patients were treated with a combination of cytoreduction surgery and heated intraperitoneal chemotherapy. 18 The biological materials (fresh frozen and formalin-fixed paraffin-embedded [FFPE] samples) were stored in the Pathology Department of Hospices Civils de Lyon Cancer Institute (Lyon, France). Clinical, demographic, and epidemiological data are available for all the patients. The appropriate ethics committees of the respective institutes approved the study.
BAP1 Sequencing
DNA extractions were performed as previously described. 17 The entire gene region (chromosome 3: 52,434,944-42,444,259 based on human genome 19, 9.316 kilobase pairs) was submitted to Agilent SureDesign software for customized probe design (Agilent Technologies, Waldbronn, Germany [https:// earray.chem.agilent.com/suredesign/home.htm]). As a result, 498 overlapping amplicons covering 100% of the gene region were selected. The design is available upon request.
Only samples with a tumor content of at least 40% were included. Libraries were prepared by using Agilent SureSelect enrichment protocols (Agilent Technologies) and sequenced on a PGM sequencer (Life Technologies, Carlsbad, CA) for an average coverage of Â1000. Fortyeight bar-coded libraries were sequenced on 318v2 chips by pools of 12. Each run contained random numbers of tumor and normal samples. Sequencing data were aligned to the human genome 19 
Statistical Analysis
Statistical analyses were performed with SAS 9.4 software (SAS, Inc., Cary, NC). We evaluated the association of BAP1 alterations (CN changes, mutations, and/or lack of protein expression) with age by using the MannWhitney test and with sex, histological type, smoking habits, and professional asbestos exposure by using Fisher's exact bilateral test. We also evaluated the role of BAP1 alterations in the overall survival of patients with peritoneal mesothelioma, which was defined as the time between the surgery and the date of death, the date of last news, or the end point date (December 31, 2015) . For survival analysis, only patients whose disease was diagnosed between 1998 and 2012 were included. Patients were followed up for a minimum period of 3 years. In the univariate analysis, 5 year-survival curves were generated according to the Kaplan-Meier method and compared between groups by the log-rank test. Factors affecting survival in univariate analysis (p 0.20), including sex as the variable of interest, were tested for their independent role in a multivariate Cox model by using a stepwise backward procedure. Hazard ratios (HRs) and 95% confidence intervals (CIs) were computed. The model chosen (including sex) had the lowest Akaike information criterion value.
Results
A total of 46 patients in whom malignant peritoneal mesothelioma had been diagnosed were included in this study (Tables 1 and Table 2 and Supplementary Data 1), 26 men and 20 women (1.3:1). Most tumors were of the epithelioid subtype (n ¼ 41), with three biphasic and two sarcomatoid tumors also. Professional exposure to asbestos was found by medical interview in 18% of the patients (all men), and 32% of the patients had a history of smoking. The median age of diagnosis was 62.5 years for men and 60 for women (see Table 1 ). The status of BAP1 was evaluated in this series as follows: BAP1 nuclear expression was assessed by IHC on 44 FFPE tumor samples, and BAP1 mutations were screened for in 34 fresh frozen tumor samples and 14 matched normal tissue samples (13 colonic and spleen tissue samples and one blood sample). In addition, CN data were available for 33 peritoneal mesotheliomas from our recently published work 17 (see Supplementary Data 1). The CN and mutational data were generated from DNA extracted from the same fresh frozen piece of tumor, whereas IHC was performed on FFPE material. Overall, we have generated CN, mutational, and protein expression data for 31 peritoneal mesotheliomas.
We identified splicing (n ¼ 4), nonsense (n ¼ 3), missense (n ¼ 3), and frameshift (n ¼ 2) mutations in BAP1 in 32% of the samples (Fig. 1A and Table 3 ). The AFs ranged from 2.5% to 61.25% (it is of note that we have considered only variants with an AF of at least 1%). For three of the mutated cases for which matched normal DNA was available, the mutation was confirmed to be somatic. These mutations were also accompanied by loss of BAP1 nuclear expression in nine of the 10 mutated samples for which IHC data were also available ( Fig. 1B and C) ; the remaining sample carried a missense mutation classified as neutral by SIFT and POLYPHEN being that the biological significance of this mutation questionable (Table 3) . We have previously reported that 42% of these samples harbored BAP1 CN loss. 17 In 10 out of the 13 samples with BAP1 CN loss on which IHC was performed, the CN loss co-occurred with the loss of BAP1 nuclear expression (see Fig. 1B) ; the remaining three samples might have retained at least one wild-type allele of BAP1. Globally, 57% of the samples analyzed showed loss of BAP1 nuclear expression (see Fig. 1B  and C) , and for most of the cases with available data (n ¼ 16), this loss of expression was explained by CN loss (n ¼ 4), mutation (n ¼ 3), or both (n ¼ 6). Overall, 73% of the peritoneal mesotheliomas analyzed carried at least one allele of BAP1 inactivated by CN loss or mutation; however, if we consider only the samples with complete inactivation of BAP1, indicated by its loss of nuclear expression, this number goes down to 57% (see Fig. 1B ).
In our series of samples, BAP1 mutations were observed only in men (see Supplementary Data 1) . The Fisher's exact test results suggest that this was due to a significant difference in occurrence by sex (p ¼ 0.003) (see Table 2 ). Similarly, professional asbestos exposure was also observed only in men (p ¼ 0.007) (see Table 1 survival for sex, age, family history of cancer, professional asbestos exposure, smoking habits, BAP1 CN, or BAP1 alteration (including CN and/or mutation and/or protein expression loss). However, we did find a significant impact on survival for age, histological type, BAP1 protein expression, and BAP1 mutation (Supplementary Data 2). The loss of BAP1 nuclear expression (HR ¼ 0.27, 95% CI: 0.09-0.79, p ¼ 0.016) (Fig. 2A) or the presence of a BAP1 mutation (HR ¼ 0.27, CI 95%: 0.07-0.96, p ¼ 0.04) (Fig. 2B ) was associated with a better overall survival independently of tumor histological type, age, and sex. We found that the variable representing the combination of having a BAP1 mutation and/ or BAP1 nuclear expression loss was also significantly associated with survival (HR ¼ 0.24, CI 95%: 0.08-0.69, p ¼ 0.007) (Fig. 2C) , although this was not the case when the information about BAP1 CN loss was added (HR ¼ 0.47, CI 95%: 0.12-1.71, p ¼ 0.25) (Supplementary Data 3) . This might be explained by the fact that nuclear BAP1 expression was observed in three samples with a CN loss but in only one harboring a mutation. This suggests that the tumor suppressor activity of BAP1 was retained in these samples in spite of the genomic alteration.
Discussion
Inactivation of BAP1 is known to play a key role in the development of both familial 11, 22 and spontaneous malignant mesothelioma. 10 In addition, Kadariya et al. have recently shown in mouse models that there is a possible gene-environment interaction between BAP1 mutations and asbestos exposure in the development of this disease. 6 In this context, Napolitano et al. found that in mice carrying heterozygous germline BAP1 mutations mesothelioma develops upon exposure to asbestos levels that rarely cause the disease in wildtype mice. 23 In a recent study on 73 malignant pleural mesotheliomas, for which mutational and CN data were available, it was found that inactivation by mutation (including rearrangements) or CN loss was detected in 30% of the cases analyzed.
14 This percentage was higher (probably owing to the low sample size) in another study, in which the authors found that inactivation of BAP1 by mutation or CN loss happened in 41% of the 22 malignant pleural mesotheliomas they analyzed. 13 Moreover, the presence of BAP1 genomic alterations seems to correlate with the loss of its protein expression, 12 and the complete loss of BAP1 protein expression, reported in 46% of malignant pleural mesotheliomas, has been associated with better survival. 24 Because of the low incidence of peritoneal mesothelioma, genomic studies on it are rare and those so far published have included only a small number of samples. 15, 16 Our recent analysis of CN alterations by using array-based comparative genomic hybridization in a set of 33 peritoneal mesotheliomas showed that pleural and peritoneal mesotheliomas harbor similar patterns of genomic alterations, including deletions in 3p21, 9p21, and 22q12.
17 BAP1 CN loss was observed in 42% of the samples. In the current study, we have complemented these data with analyses of mutational and protein expression data. We found that BAP1 mutations occurred in 32% of the cases. Although it has been shown that patients with germline BAP1 mutations have improved survival relative to those with somatic mutations, 25 the unavailability of the germline status in most of our samples limited our investigation of this aspect. Surprisingly, in our study BAP1 mutations were present only in men, although BAP1 mutations in women with peritoneal mesotheliomas have been recently reported. 16 Whether the sex bias we have observed in BAP1 mutation status is the result of a biological difference or a sampling issue remains unclear. It was also striking the similar frequency of peritoneal mesotheliomas in both men and women because for pleural mesotheliomas this ratio is usually higher in men. Also, the total lack of asbestos exposure and BAP1 mutations in the women included in our series (see Table 1 ) suggests that there might be additional factors causing peritoneal mesotheliomas aside from asbestos, probably through alternate pathogenic mechanisms as was recently proposed in a study in an Eastern China population. 26 Loss of nuclear localization is required for BAP1-mediated tumor suppressor activity 1 ; however, there was no perfect match between the presence of a CN deletion or mutation and the loss of BAP1 nuclear expression, suggesting a heterozygous inactivation of BAP1 in those cases that retained some nuclear expression. Besides, CN loss or mutation did not explain all the cases with loss of BAP1 nuclear expression, suggesting that additional mechanisms may be resulting in the inactivation of BAP1, such as genomic rearrangements 14 or epigenetic inactivation. These data also suggest, as was recently pointed out by Yoshikawa et al., 27 that integrative analyses of different technologies are required to capture the full spectrum of BAP1 gene alterations in malignant mesotheliomas. Overall, loss of BAP1 nuclear expression, and therefore of its complete tumor suppressor activity, was observed in 57% of the cases. This loss of activity was underestimated when only CN or mutational analyses were considered, hinting at IHC being the most reliable measurement of BAP1 activity, as previously proposed by Nasu et al. 12 However, it is of note that 13% of the remaining samples carried a heterozygous inactivation of BAP1 because some nuclear protein expression was detected. Nevertheless, the biological consequences of reduced BAP1 levels in the development of cancer are still unclear.
In our data the presence of a BAP1 mutation or the loss of BAP1 nuclear expression was correlated with a better survival independently of age, sex, and tumor histological type, but this was not the case for CN loss-probably because three of these samples retained BAP1 nuclear expression. The unexpected finding that lack of expression correlates with an improved prognosis in mesothelioma was initially proposed by Arzt et al. in a series of 123 malignant pleural mesotheliomas, 28 and subsequently, several papers suggested that there was a trend of improved prognosis also in carriers of BAP1 somatic mutations. 24 However, the results observed in mesothelioma contradict those reported for other cancer types carrying BAP1 inactivation, such as uveal melanomas, 29 clear cell renal cell carcinomas, 30 or gliomas. 31 This might be explained by other factors contributing to the development of these diseases rather than by a pleiotropic effect of BAP1 in different tissues. It is worth mentioning that the loss of BAP1 expression was observed only in the epithelioid type, and although this might be related to the limited representation of the other histological types in our series, these data are in line with previous studies on pleural mesothelioma. 32 In this study, which is the largest so far described in the literature, we found that BAP1 inactivation is very frequent in malignant peritoneal mesothelioma and that its loss of nuclear expression is associated with better survival. In line with the guidelines given by the consensus report of the 2015 Weinman International Conference on Mesothelioma 33 for the screening of BAP1 germline mutations in the context of the BAP1 cancer syndrome, we believe that in the context of peritoneal mesothelioma (and probably in malignant mesotheliomas in general), BAP1 IHC should be routinely assessed, considering its prognostic value. Besides, BAP1 status can also serve as a differential diagnosis marker to distinguish pleural mesothelioma from lung cancer, 34, 35 to distinguish peritoneal mesothelioma from peritoneal serous carcinomas, 36 and to facilitate the histological classification of mesotheliomas. 37 
